<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146937</url>
  </required_header>
  <id_info>
    <org_study_id>J1408</org_study_id>
    <secondary_id>NA_00092522</secondary_id>
    <nct_id>NCT02146937</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance</brief_title>
  <official_title>A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single site, single arm Phase II study to evaluate the combination of&#xD;
      bicalutamide plus finasteride in men with MRI detectable significant prostate nodules&#xD;
      followed on active surveillance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done to determine the negative re-biopsy rate as determined by&#xD;
      MRI/TRUS fusion guided biopsy targeting the dominant nodule site defined by pre-treatment MRI&#xD;
      following three months (90 days) of combination bicalutamide plus finasteride.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to lack of accrual for this study. PI decided to close the study.&#xD;
  </why_stopped>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative re-biopsy rate</measure>
    <time_frame>three months (90 days)</time_frame>
    <description>To determine the negative re-biopsy rate as determined by MRI/TRUS fusion guided biopsy targeting the dominant nodule site defined by pre-treatment MRI following three months (90 days) of combination bicalutamide plus finasteride.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of exit at 2 years from the active surveillance program at Johns Hopkins due to pathologic upstaging following treatment with bicalutamide plus finasteride.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA progression rates and PSA progression free survival (PFS), as defined by the Prostate Cancer Working Group 2 (PCWG2) criteria, at 2 years [Scher et al, 2008].</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of radiographic disappearance of MRI detectable prostate cancer following treatment with combination bicalutamide plus finasteride (i.e., decrease in size of the target prostate cancer nodule below 5 mm).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as assessed by the revised National Cancer Institute Common Toxicity Criteria (NCI CTC), version 4.0 published 14 June 2010.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life utilizing the FACT-P and SF36 surveys</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall rate of exit at 2 years from the active surveillance program at Johns Hopkins following treatment with bicalutamide plus finasteride.</measure>
    <time_frame>two years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of local treatment (e.g., radical prostatectomy, radiation therapy, brachytherapy) at 2 years and the local treatment free survival</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Detectable Prostate Nodules</condition>
  <arm_group>
    <arm_group_label>Combination therapy- bicalutamide and finasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide plus Finasteride- Combination therapy</intervention_name>
    <description>3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily</description>
    <arm_group_label>Combination therapy- bicalutamide and finasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent.&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Eastern cooperative group (ECOG) performance status ≤2&#xD;
&#xD;
          4. Documented histologically confirmed adenocarcinoma of the prostate (minimum 12 core&#xD;
             prostate biopsy completed within 90 days of screening)&#xD;
&#xD;
          5. Very low-risk prostate cancer as defined by:&#xD;
&#xD;
               -  Gleason score ≤ 6&#xD;
&#xD;
               -  PSA density ≤ 0.15 ng/mL/mL&#xD;
&#xD;
               -  PSA &lt; 10 ng/mL&#xD;
&#xD;
               -  Clinical tumor stage T1 (cT1) (i.e., no palpable nodule by digital rectal exam)&#xD;
&#xD;
               -  ≤2 prostate cores positive for prostatic adenocarcinoma&#xD;
&#xD;
               -  ≤50% of any given core involved by prostatic adenocarcinoma&#xD;
&#xD;
          6. Willing and qualified for active surveillance at Johns Hopkins&#xD;
&#xD;
          7. Presence of at least one MRI significant visible prostate tumor (i.e., ≥5 mm in at&#xD;
             least one dimension) that has been biopsy proven to be prostatic adenocarcinoma Note:&#xD;
             MRI may occur pre- or post-prostate biopsy. If done post-biopsy, the MRI must not&#xD;
             occur &lt;8 weeks post-prostate biopsy.&#xD;
&#xD;
          8. Serum testosterone ≥150 ng/dL&#xD;
&#xD;
          9. Able to swallow the study drugs whole as a tablet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior local therapy to treat prostate cancer (e.g., radical prostatectomy, radiation&#xD;
             therapy, brachytherapy)&#xD;
&#xD;
          2. Prior use of bicalutamide&#xD;
&#xD;
          3. Prior use of finasteride within the past year&#xD;
&#xD;
          4. Prior or ongoing systemic therapy for prostate cancer including, but not limited to:&#xD;
&#xD;
               -  Hormonal therapy (e.g., leuprolide, goserelin, triptorelin)&#xD;
&#xD;
               -  CYP-17 inhibitors (e.g., abiraterone, ketoconazole)&#xD;
&#xD;
               -  Antiandrogens (e.g., bicalutamide, flutamide, nilutamide)&#xD;
&#xD;
               -  Second generation antiandrogens (e.g., enzalutamide, ARN-509)&#xD;
&#xD;
               -  Immunotherapy (e.g., sipuleucel-T, ipilimumab)&#xD;
&#xD;
               -  Chemotherapy (e.g., docetaxel, cabazitaxel)&#xD;
&#xD;
          5. Evidence of serious and/or unstable pre-existing medical, psychiatric or other&#xD;
             condition (including laboratory abnormalities) that could interfere with patient&#xD;
             safety or provision of informed consent to participate in this study.&#xD;
&#xD;
          6. Any psychological, familial, sociological, or geographical condition that could&#xD;
             potentially interfere with compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
          7. Abnormal bone marrow function [absolute neutrophil count (ANC)&lt;1500/mm3, platelet&#xD;
             count &lt;100,000/mm3, hemoglobin &lt;9 g/dL]&#xD;
&#xD;
          8. Abnormal liver function (bilirubin, AST, ALT ≥ 3 x upper limit of normal)&#xD;
&#xD;
          9. Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)&#xD;
&#xD;
         10. Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III&#xD;
             or IV heart failure or history of a prior myocardial infarction (MI) within the last&#xD;
             five years prior to enrollment in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Pienta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 1, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>active surveillance</keyword>
  <keyword>MRI/transrectal ultrasound fusion guided biopsy</keyword>
  <keyword>biopsy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

